SCHEMBL6474231

SCHEMBL6474231

CCN(CC)c1ccc(CCCc2ccc(Nc3ccccc3C(=O)OC)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
ALOX15 P16050 1/20 0.56
SIRT2 Q8IXJ6 2/20 0.47
NPC1 O15118 4/20 0.45
RAB9A P51151 3/20 0.45
KDM4E B2RXH2 3/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
KMT2A Q03164 6/20 0.45
MEN1 O00255 5/20 0.45
NOX1 Q9Y5S8 3/20 0.45
ALDH1A1 P00352 3/20 0.45
MCL1 Q07820 1/20 0.45
POLB P06746 2/20 0.43
ATM Q13315 1/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474913 0.88 MEN1 (0.55) MAPTSIRT2NPC1RAB9ALMNA
SCHEMBL6476004 0.84 MAPT (0.59) MAPTALOX15SIRT2KDM4ESMN1; SMN2
SCHEMBL6485882 0.83 MAPT (0.61) MAPTALOX15SIRT2KDM4EKMT2A
SCHEMBL6474259 0.83 MEN1 (0.60) MAPTSIRT2NPC1RAB9AKDM4E
Hydrochloric Acid SCHEMBL6474052 0.81 MEN1 (0.58) MAPTSIRT2NPC1RAB9AKDM4E
SCHEMBL6482938 0.79 MEN1 (0.53) MAPTSIRT2KMT2AMEN1ALDH1A1
SCHEMBL6474311 0.79 KMT2A (0.69) MAPTALOX15SIRT2KDM4ELMNA
SCHEMBL6475251 0.79 MEN1 (0.56) MAPTSIRT2SMN1; SMN2KMT2AMEN1
SCHEMBL6474928 0.79 SIRT1 (0.50) SIRT2NPC1RAB9AKMT2AMEN1
SCHEMBL8834851 0.79 MAPT (0.56) MAPTALOX15NPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MAPT 6/4885ALOX15 2982/4885SIRT2 2735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.